相似文献
1
Targeting tumor-associated myeloid cells for cancer immunotherapy.
Oncoimmunology. 2015 Apr 2;4(3):e983961. doi: 10.4161/2162402X.2014.983761. eCollection 2015 Mar.
2
Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
J Immunother Cancer. 2017 Aug 15;5(1):64. doi: 10.1186/s40425-017-0266-x.
3
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Adv Cancer Res. 2015;128:95-139. doi: 10.1016/bs.acr.2015.04.002. Epub 2015 May 12.
4
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Biomaterials. 2019 Oct;219:119401. doi: 10.1016/j.biomaterials.2019.119401. Epub 2019 Jul 31.
5
Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
FEBS J. 2018 Feb;285(4):717-733. doi: 10.1111/febs.14288. Epub 2017 Oct 26.
6
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
Cancers (Basel). 2020 Sep 15;12(9):2626. doi: 10.3390/cancers12092626.
7
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):113-123. doi: 10.1007/s00005-017-0492-4. Epub 2017 Oct 14.
8
Suppression of T cells by myeloid-derived suppressor cells in cancer.
Hum Immunol. 2017 Feb;78(2):113-119. doi: 10.1016/j.humimm.2016.12.001. Epub 2016 Dec 7.
9
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Front Immunol. 2018 Jun 4;9:1288. doi: 10.3389/fimmu.2018.01288. eCollection 2018.
10
Myeloid suppressor cells in cancer and autoimmunity.
J Autoimmun. 2017 Dec;85:117-125. doi: 10.1016/j.jaut.2017.07.010. Epub 2017 Jul 17.
引用本文的文献
1
Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy.
Front Immunol. 2025 Jan 21;15:1471399. doi: 10.3389/fimmu.2024.1471399. eCollection 2024.
2
characterization and analysis of glioblastoma at different stages using multiscale photoacoustic molecular imaging.
Photoacoustics. 2023 Feb 13;30:100462. doi: 10.1016/j.pacs.2023.100462. eCollection 2023 Apr.
3
Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer.
Nat Commun. 2022 Nov 28;13(1):7316. doi: 10.1038/s41467-022-35096-6.
4
Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
Front Med Technol. 2021 Nov 22;3:791596. doi: 10.3389/fmedt.2021.791596. eCollection 2021.
5
Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23714-23723. doi: 10.1073/pnas.1906346116. Epub 2019 Nov 11.
6
Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.
Front Cell Infect Microbiol. 2018 Sep 21;8:332. doi: 10.3389/fcimb.2018.00332. eCollection 2018.
7
Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma.
Oncoimmunology. 2016 Sep 20;5(11):e1234565. doi: 10.1080/2162402X.2016.1234565. eCollection 2016.
8
CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells.
Oncoimmunology. 2016 Sep 26;5(10):e1226719. doi: 10.1080/2162402X.2016.1226719. eCollection 2016.
9
Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma.
Oncoimmunology. 2016 Jan 19;5(5):e1130206. doi: 10.1080/2162402X.2015.1130206. eCollection 2016 May.
本文引用的文献
1
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9. doi: 10.1073/pnas.1410626111. Epub 2014 Jul 28.
2
Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.
Nat Med. 2014 Jun;20(6):676-81. doi: 10.1038/nm.3560. Epub 2014 May 25.
3
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Blood. 2013 Apr 11;121(15):2975-87. doi: 10.1182/blood-2012-08-448548. Epub 2013 Jan 15.
4
S100A9 a new marker for monocytic human myeloid-derived suppressor cells.
Immunology. 2012 Jun;136(2):176-83. doi: 10.1111/j.1365-2567.2012.03566.x.
5
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
J Clin Oncol. 2011 Jul 10;29(20):2787-94. doi: 10.1200/JCO.2010.33.3005. Epub 2011 May 31.
6
Myeloid-derived suppressor cell heterogeneity and subset definition.
Curr Opin Immunol. 2010 Apr;22(2):238-44. doi: 10.1016/j.coi.2010.01.021. Epub 2010 Feb 17.
7
Myeloid-derived suppressor cells as regulators of the immune system.
Nat Rev Immunol. 2009 Mar;9(3):162-74. doi: 10.1038/nri2506.
8
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
J Clin Oncol. 2007 Jun 20;25(18):2546-53. doi: 10.1200/JCO.2006.08.5829.
9
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
N Engl J Med. 2004 Nov 18;351(21):2159-69. doi: 10.1056/NEJMoa041869.
10
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
Nat Med. 1999 Oct;5(10):1171-7. doi: 10.1038/13928.
Zotero 插件